AlgoTherapeutix blames a “strong placebo effect” for the mid-stage failure for its pain gel ATX01, but the company still ...

Vertex (VRTX) stock was trading largely flat post-market after the company released its Q4 earnings report and issued 2025 ...

Vertex Pharmaceuticals is working toward making its recently approved non-opioid pain medicine Journavx not only broadly ...

Vertex Pharmaceuticals (VRTX) reports Q4 earnings today. Investors are eager for updates on new drug launches and growth ...

Vertex Pharmaceuticals recently obtained approval for its non-opioid pain medication. The drug could become a blockbuster and a key part of Vertex's portfolio. The stock has been rising in value ...

Revenue $2.91 billion $2.78 billion $2.52 billion 15.7% Net Income (non-GAAP) $1.04 billion N/A $1.10 billion (5.5%) R&D and SG&A expenses (non-GAAP) $1.21 billion N/A $984 million 22.9% Vertex ...

HOUSTON, January 22, 2025--(BUSINESS WIRE)--Vertex Energy, Inc. ("Vertex" or the "Company"), a leading specialty refiner and marketer of high-quality refined products, together with its affiliates ...

Specialization is for insects.” So, in the interest of not being insects, here are my top-five physics equations you should know. 1. Newton’s Second Law I’m sure you've seen this one before ...

A novel Vertex Pharmaceuticals drug that takes a new approach to pain is now approved by the FDA, a landmark decision for a first-in-class product that brings patients a treatment alternative ...

CNBC's Becky Quick reports on the latest news. Russia and US to meet for talks on Ukraine’s future after sidelined European leaders gather for emergency summit 'Always Sunny' Star Offers to Pay ...

Conestoga Capital Advisors, an asset management company, released its fourth-quarter 2024 investor letter. A copy of the ...